Nothing Special   »   [go: up one dir, main page]

ATE309271T1 - Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen - Google Patents

Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen

Info

Publication number
ATE309271T1
ATE309271T1 AT97926514T AT97926514T ATE309271T1 AT E309271 T1 ATE309271 T1 AT E309271T1 AT 97926514 T AT97926514 T AT 97926514T AT 97926514 T AT97926514 T AT 97926514T AT E309271 T1 ATE309271 T1 AT E309271T1
Authority
AT
Austria
Prior art keywords
methods
binding protein
prevention
cna
dna segments
Prior art date
Application number
AT97926514T
Other languages
English (en)
Inventor
Magnus Hoeoek
Joseph M Patti
Karen House-Pompeo
Narayana Sthanam
Jindrich Symersky
Original Assignee
Texas A & M Univ Sys
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A & M Univ Sys, Uab Research Foundation filed Critical Texas A & M Univ Sys
Application granted granted Critical
Publication of ATE309271T1 publication Critical patent/ATE309271T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97926514T 1996-05-16 1997-05-14 Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen ATE309271T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1767896P 1996-05-16 1996-05-16
PCT/US1997/008210 WO1997043314A2 (en) 1996-05-16 1997-05-14 Collagen binding protein compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE309271T1 true ATE309271T1 (de) 2005-11-15

Family

ID=21783969

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926514T ATE309271T1 (de) 1996-05-16 1997-05-14 Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen

Country Status (9)

Country Link
US (2) US6288214B1 (de)
EP (1) EP0950068B1 (de)
AT (1) ATE309271T1 (de)
AU (1) AU3126097A (de)
CA (1) CA2255669A1 (de)
DE (1) DE69734601T2 (de)
DK (1) DK0950068T3 (de)
ES (1) ES2252785T3 (de)
WO (1) WO1997043314A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309271T1 (de) * 1996-05-16 2005-11-15 Texas A & M Univ Sys Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
CA2341177A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
CN1314450C (zh) * 1998-08-31 2007-05-09 英希比泰克斯公司 多组分疫苗
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
EP1177203B1 (de) * 1999-05-10 2011-10-05 The Texas A&M University System Kollagen-bindende proteine von enterococcalen bakterien
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
JP4393739B2 (ja) 1999-08-02 2010-01-06 ソフトバンクＢｂ株式会社 電子決済システム、決済装置及び端末
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
JP2003527440A (ja) 2000-03-17 2003-09-16 インヒビテックス インコーポレーテッド コラーゲン結合蛋白質からの交差反応性追放抗体および同定方法および使用
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
ATE524195T1 (de) * 2001-01-26 2011-09-15 Inhibitex Inc Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
JP2002253712A (ja) * 2001-03-02 2002-09-10 Endo Mfg Co Ltd ゴルフクラブ
EP1443957A4 (de) * 2001-05-08 2005-10-12 Texas A & M Univ Sys Oberflächenproteine aus grampositiven bakterien mit hochkonservierten motiven sowie diese erkennende antikörper
EP1395272A4 (de) 2001-05-11 2005-10-26 Texas A & M Univ Sys Verfahren und zusammensetzungen zur hemmung der durch thrombin induzierten blutgerinnung
US6841154B2 (en) 2001-06-15 2005-01-11 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus
US7115264B2 (en) * 2001-11-05 2006-10-03 Inhibitex Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections
US20030153026A1 (en) * 2002-01-04 2003-08-14 Javier Alarcon Entrapped binding protein as biosensors
US6855556B2 (en) 2002-01-04 2005-02-15 Becton, Dickinson And Company Binding protein as biosensors
WO2003072607A1 (en) * 2002-02-21 2003-09-04 Università Degli Studi Di Pavia Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
EP1481011A4 (de) * 2002-03-05 2007-05-30 Inhibitex Inc Monoklonale und polyklonale antikörper, die koagulasenegative staphylokokkenproteine erkennen
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
EP1754059B1 (de) * 2004-06-09 2010-08-04 Becton, Dickinson and Company Sensor für mehrere analyte
CA2580103C (en) 2004-09-22 2021-11-16 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2006078213A1 (en) * 2005-01-20 2006-07-27 Isconova Ab Vaccine composition comprisinga fibronectin binding protein or a fibronectin binding peptide
JP4726109B2 (ja) * 2005-02-10 2011-07-20 昭和電工株式会社 皮膚外用剤、それを用いる皮膚有害微生物の付着予防方法及び増殖防止方法
ES2586125T3 (es) * 2005-02-14 2016-10-11 Epitopix, Llc Polipéptidos de Staphylococcus aureus y métodos de uso
US8475798B2 (en) * 2005-06-16 2013-07-02 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
EP1909868A1 (de) * 2005-07-25 2008-04-16 Nanotechnology Victoria PTY Ltd Mikroarray-vorrichtung
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
AU2007221321B2 (en) * 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP5337691B2 (ja) 2006-04-20 2013-11-06 ベクトン・ディキンソン・アンド・カンパニー 熱安定性タンパク質ならびにその作製方法および使用方法
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR101661946B1 (ko) * 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP2341929B1 (de) 2008-10-06 2017-01-25 University Of Chicago Zusammensetzungen und verfahren im zusammenhang mit bakteriellen emp proteinen
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
CN105582524A (zh) 2009-03-23 2016-05-18 埃皮托皮克斯有限责任公司 多肽和含有革兰氏阳性多肽的免疫组合物及使用方法
JP5747370B2 (ja) * 2009-03-31 2015-07-15 国立大学法人浜松医科大学 高病原性口腔細菌の高感度検出法
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
EP3281947B1 (de) 2009-04-03 2020-02-12 The University of Chicago Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (de) * 2009-08-10 2011-02-16 Kenta Biotech AG Menschlicher monoklonaler Antikörper gegen S.aureus aus Alpha-Toxin und seine Verwendung bei der Behandlung oder Vorbeugung der Abszessbildung
WO2011111790A1 (ja) 2010-03-10 2011-09-15 国立大学法人浜松医科大学 高病原性口腔細菌による腸炎誘発原因分子の産生とその高感度検出法
US8821894B2 (en) 2010-07-02 2014-09-02 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US8182842B1 (en) 2010-11-10 2012-05-22 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Physico-chemical-managed killing of penicillin-resistant static and growing gram-positive and gram-negative vegetative bacteria
US8440618B2 (en) * 2011-01-19 2013-05-14 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Composition for the attachment of implants to collagen or other components of biological tissue
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
AU2012287513A1 (en) 2011-07-22 2014-03-13 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and compositions for vaccinating against Staphylococcus aureus
AU2012296576B2 (en) 2011-08-15 2017-09-07 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
CA2910319C (en) 2012-04-26 2022-06-14 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2013162751A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
MX2015012681A (es) 2013-03-15 2018-05-17 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Composiciones y metodos para tratar patogenos fungicos y bacterianos.
US11531028B2 (en) 2013-05-10 2022-12-20 Nordic Bioscience A/S Collagen type X alpha-1 assay
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
WO2017087838A2 (en) * 2015-11-19 2017-05-26 George Mason University Dual inhibitory action peptidomimetic inhibitor for il-33 and il-1beta
EP3426287A4 (de) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Verfahren und kits zur verwendung bei der vorbeugung und behandlung von vulvovaginaler candidose
JP2022505871A (ja) 2018-10-23 2022-01-14 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189015A (en) * 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
SE9003374D0 (sv) * 1990-10-22 1990-10-22 Alfa Laval Agri Int A collagen binding protein as well as its preparation
US5851794A (en) * 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5980908A (en) * 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6013482A (en) * 1996-10-15 2000-01-11 Smithkline Beecham Plc Cell surface protein compounds
US5858709A (en) * 1996-10-15 1999-01-12 Smithkline Beecham P.L.C. Fibronectin binding protein B compounds
ATE309271T1 (de) * 1996-05-16 2005-11-15 Texas A & M Univ Sys Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
US5789171A (en) * 1996-06-20 1998-08-04 Board Of Trustees Of The University Of Arkansas Use of cna, fnba, fnbb, and hlb, gene probes for the strain-specific identification of Staphylococcus aureus

Also Published As

Publication number Publication date
CA2255669A1 (en) 1997-11-20
AU3126097A (en) 1997-12-05
DE69734601D1 (de) 2005-12-15
US20020102262A1 (en) 2002-08-01
WO1997043314A2 (en) 1997-11-20
EP0950068B1 (de) 2005-11-09
DE69734601T2 (de) 2006-08-03
EP0950068A2 (de) 1999-10-20
ES2252785T3 (es) 2006-05-16
WO1997043314A3 (en) 1997-12-24
DK0950068T3 (da) 2006-02-13
US6288214B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
ATE309271T1 (de) Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
ATE168272T1 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
ATE251464T1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
CA2340304A1 (en) Multicomponent vaccines
DE60130468D1 (de) Zusammensetzungen und verfahren zur behandlung von chlamydia-infektionen
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
ATE461709T1 (de) Choline-bindende proteine derivate aus pneumokoken als impfstoff
NZ512574A (en) Novel streptococcus antigens useful as vaccines
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
EA200000860A1 (ru) Выделенный полинуклеотид (варианты), полинуклеотид (варианты), вектор (варианты), клетка-хозяин (варианты), выделенный полипептид (варианты), способ его получения (варианты), вакцинная композиция (варианты), способ терапевтического или профилактического лечения стрептококковой бактериальной инфекции у животного (варианты), применение (варианты)
PT750672E (pt) Sequencias de adn para metaloproteases matriciais, sua preparacao e utilizacao.
BR0010155A (pt) Proteìnas isolada, e quimérica, composição, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição de vacina recombinante ou composição de vacina atenuada, composição farmacêutica, métodos de imunizar um indivìduo contra um imunógeno, proteìna não-cd80 isolada, molécula de ácido nucleico, e, método de imunossuprimir um indivìduo
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
DE69841073D1 (de) Fibronektinbindungsprotein abgeleitete peptide, die nicht an fibronektin binden, antikörper dagegen und therapeutische anwendung
ATE237691T1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
DE69833568D1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
WO2024130155A3 (en) Swine influenza vaccine compositions and methods thereof
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
ATE401349T1 (de) Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen
TH64256A3 (th) องค์ประกอบของโปรตีนที่ถูกทำให้เสถียร

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0950068

Country of ref document: EP

REN Ceased due to non-payment of the annual fee